Frost & Sullivan Independent Equity Research

DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.


Company: DNA Biomedical Solutions Ltd.        

Sector: Healthcare

Report type: Quarterly update

Published on: February 5, 2018

DNA research articles: